New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension

Stone JH, Spotswood H, Unizony SH, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Rheumatology Oxford University Press

DOI: 10.1093/rheumatology/keab780

Abstract

Objective. Tocilizumab plus prednisone induces sustained glucocorticoid-free remission in patients with GCA. However, its long-term benefits in new-onset vs relapsing disease are uncertain, and the value of weekly vs everyother-week dosing has not been evaluated.

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Harvard University US United States (USA) (US) Roche Products Limited and Roche Diagnostics Limited GB United Kingdom (GB) Technische Universität Dresden DE Germany (DE) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven BE Belgium (BE) University of Groningen / Rijksuniversiteit Groningen NL Netherlands (NL) Universitat de Barcelona (UB) / University of Barcelona ES Spain (ES) Mid and South Essex NHS Foundation Trust GB United Kingdom (GB) Azienda Unità Sanitaria Locale die Reggio Emilia IT Italy (IT) Hospital for Special Surgery (HSS) US United States (USA) (US) Genentech Inc. US United States (USA) (US)

How to cite

APA:

Stone, J.H., Spotswood, H., Unizony, S.H., Aringer, M., Blockmans, D., Brouwer, E.,... Bao, M. (2021). New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology. https://doi.org/10.1093/rheumatology/keab780

MLA:

Stone, John H., et al. "New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension." Rheumatology (2021).

BibTeX: Download